Sales Performance - Sales for the three months ended February 28, 2025 increased 0.6 percent to $6.1 billion, with a 4.1 percent increase on a constant currency basis [263]. - Sales for the six months ended February 28, 2025 increased 5.3 percent to $12.5 billion, with a 5.3 percent increase on a constant currency basis [272]. - Pharmacy sales decreased 6.7 percent in the three months ended February 28, 2025, with comparable pharmacy sales in constant currency increasing 3.6 percent [264]. - Pharmacy sales decreased 4.1 percent in the six months ended February 28, 2025, with comparable pharmacy sales in constant currency increasing 5.9 percent [273]. - Retail sales increased 1.1 percent for the three months ended February 28, 2025, with comparable retail sales in constant currency increasing 4.5 percent [265]. - Retail sales increased 5.1 percent for the six months ended February 28, 2025, with comparable retail sales in constant currency increasing 5.8 percent [274]. - Sales for the three months ended February 28, 2025 decreased by $23 million to $2.2 billion, with VillageMD sales down $101 million to $1.5 billion, while CareCentrix and Shields saw increases of 6.5% to $390 million and 29.7% to $183 million respectively [285]. - Sales for the six months ended February 28, 2025 increased by $218 million to $4.3 billion, with VillageMD sales up $24 million to $3.1 billion, and CareCentrix and Shields also showing significant growth [293]. Operating Income and Profitability - Operating income for the three months ended February 28, 2025 decreased 51.7 percent to $101 million, impacted by currency translation and cost inflation [269]. - Adjusted operating income for the three months ended February 28, 2025 decreased 4.7 percent to $234 million, reflecting cost inflation and technology investments [271]. - Operating income for the six months ended February 28, 2025 decreased 25.5 percent to $242 million, influenced by cost inflation and technology investments [278]. - Adjusted operating income for the six months ended February 28, 2025 increased 3.6 percent to $401 million, driven by strong retail performance and market growth [279]. - Gross profit for the three months ended February 28, 2025 was $346 million, an increase of $155 million compared to the same quarter last year, driven by higher contributions from VillageMD and growth at Shields [286]. - Gross profit for the six months ended February 28, 2025 was $585 million, an increase of $269 million compared to the year-ago period, driven by contributions from VillageMD and Shields [294]. - Adjusted operating income for the three months ended February 28, 2025 improved by $150 million to $117 million, driven by higher contributions from VillageMD and growth at Shields [291]. - Adjusted EBITDA for the three months ended February 28, 2025 was $158 million, an improvement of $140 million compared to the same quarter last year, reflecting growth at VillageMD and Shields [292]. - Adjusted operating income for the six months ended February 28, 2025 improved by $271 million to $142 million, reflecting better performance from VillageMD and Shields [297]. - Adjusted EBITDA for the six months ended February 28, 2025 was $228 million, an improvement of $250 million compared to the year-ago period, indicating strong operational performance [298]. Net Loss and Impairments - The net loss attributable to Walgreens Boots Alliance for the six months ended February 28, 2025, was $3,118 million, compared to a net loss of $5,975 million for the same period in 2024, indicating an improvement of 47.9% [311]. - The company recorded an impairment of goodwill, intangibles, and long-lived assets amounting to $5,343 million for the six months ended February 28, 2025, down from $13,090 million in the prior year, a reduction of 59.1% [311]. - Total adjustments to operating loss for the six months ended February 28, 2025, amounted to $7,190 million, compared to $14,797 million for the same period in 2024, a decrease of 51.5% [311]. - The company recorded pre-tax gains of $157 million related to the change in classification of its previously held equity method investment in BrightSpring [12]. - The Company had total operating lease obligations of $22.1 billion, with $2.4 billion classified as current [333]. - Total non-cash impairment charges for goodwill and long-lived assets were $5.4 billion and $5.7 billion for the three and six months ended February 28, 2025, respectively [9]. Cash Flow and Financing Activities - Cash, cash equivalents, and restricted cash were $1.2 billion as of February 28, 2025, down from $3.2 billion as of August 31, 2024 [324]. - The Company had outstanding total debt of $8.0 billion as of February 28, 2025, with $1.4 billion classified as current [330]. - Net cash used for operating activities improved to $339 million for the six months ended February 28, 2025, compared to $918 million for the same period in 2024 [339]. - Negative operating cash flows for the six months ended February 28, 2025 were primarily due to legal settlements totaling $1.1 billion [340]. - Net cash provided by investing activities was $342 million for the six months ended February 28, 2025, down from $902 million in the prior year [341]. - Total additions to property, plant, and equipment were $503 million for the six months ended February 28, 2025, compared to $858 million in the same period of 2024 [344]. - Net cash used for financing activities increased significantly to $2.0 billion for the six months ended February 28, 2025, compared to $127 million in the prior year [345]. - The Company suspended its cash dividend, which totaled $432 million in the six months ended February 28, 2025, down from $828 million in the same period of 2024 [350]. - As of February 28, 2025, the Company had repurchased $8.0 billion of its $10.0 billion stock repurchase program [351]. Strategic Initiatives and Outlook - The Company anticipates cash needs over the next several years, including litigation and debt refinancing, as part of its decision to suspend cash dividends [321]. - The Company is exploring strategic monetization of non-core assets to provide additional liquidity [325]. - The Company's long-term credit ratings were downgraded to BB- with a negative outlook by Standard & Poor's and Ba3 with a stable outlook by Moody's [355].

Financial Performance - Second quarter sales increased 4.1% year-over-year to $38.6 billion, with a 4.7% increase on a constant currency basis[5] - Adjusted earnings per share (EPS) decreased 47.3% to $0.63 compared to $1.20 in the year-ago quarter[11] - Net loss for the second quarter was $2.9 billion, a 51.7% decrease from a net loss of $5.9 billion in the year-ago quarter[9] - Operating loss for the second quarter was $5.6 billion, an improvement from a loss of $13.2 billion in the year-ago quarter[7] - The net loss attributable to Walgreens Boots Alliance for the three months ended February 28, 2025, was $2,853 million, a reduction from a net loss of $5,908 million in the same period last year, reflecting a decrease of 51.7%[51] - Net loss for the six months ended February 29, 2025, was $4,640 million, a significant improvement from a net loss of $12,600 million in the same period of 2024, representing a reduction of approximately 63.2%[55] - The diluted net loss per common share (GAAP) for the six months ended February 28, 2025, was $(3.61), compared to $(6.93) for the same period in 2024, indicating an improvement of 47.9%[68] Sales and Revenue - U.S. Retail Pharmacy segment sales increased 5.3% to $30.4 billion, with comparable sales up 8.2%[21] - International segment sales were $6.1 billion, a 0.6% increase, with a 4.1% increase on a constant currency basis[26] - For the three months ended February 28, 2025, Walgreens Boots Alliance reported sales of $38,588 million, an increase from $37,052 million for the same period in 2024, representing a growth of 4.1%[51] - Total sales for the three months ended February 28, 2025, were $38,588 million, compared to $37,052 million for the same period in 2024, representing a year-over-year increase of approximately 4.1%[73] - The U.S. Retail Pharmacy segment reported sales of $30,380 million for the three months ended February 28, 2025, compared to $28,861 million for the same period in 2024, marking an increase of about 5.3%[73] Cash Flow and Assets - Free cash flow was negative $418 million, a $192 million improvement compared to the year-ago quarter[12] - Cash flows from operating activities showed a net cash used of $339 million for the six months ended February 29, 2025, compared to $918 million for the same period in 2024, indicating a 63.1% improvement[55] - The company reported a net cash provided by investing activities of $342 million for the six months ended February 29, 2025, down from $902 million in the prior year, reflecting a decrease of 62.1%[55] - Total assets decreased to $70,216 million as of February 28, 2025, down from $81,037 million as of August 31, 2024, representing a decline of 13.4%[52] - Walgreens Boots Alliance's cash and cash equivalents decreased to $702 million as of February 28, 2025, down from $1,319 million as of August 31, 2024, a decline of 46.9%[52] Strategic Initiatives - The company is withdrawing fiscal 2025 guidance due to a pending acquisition by Sycamore Partners[3] - The merger with Sycamore Partners is expected to close in the fourth quarter of calendar year 2025, pending approvals[35] - The company aims to enhance its business strategies and is currently undergoing a strategic review, which includes potential mergers and acquisitions[37] - Walgreens Boots Alliance is focused on cost-saving initiatives and growth strategies, including the Footprint Optimization Program, to improve financial performance moving forward[37] Impairments and Charges - The company reported a goodwill impairment charge of $3,653 million for the three months ended February 28, 2025, consistent with the charge of $12,369 million in the same period last year[51] - The company incurred impairment of goodwill, intangibles, and long-lived assets of $5,343 million for the three months ended February 28, 2025, compared to $13,090 million for the same period in 2024, a reduction of 59.1%[67] - The company recognized impairment of goodwill, intangibles, and long-lived assets of $3,252 million for the three months ended February 28, 2025[75] Operating Performance - The company's gross profit for the six months ended February 28, 2025, was $13,714 million, slightly down from $13,811 million in the prior year, indicating a decrease of 0.7%[51] - The adjusted gross profit for the three months ended February 28, 2025, was $6,963 million, slightly down from $7,068 million in the same period of 2024, indicating a decrease of about 1.5%[73] - The adjusted operating income for the three months ended February 28, 2025, was $785 million, down from $900 million in the same period of 2024, reflecting a decline of approximately 12.8%[74] - U.S. Healthcare segment reported an operating loss of $3,304 million for the three months ended February 28, 2025, compared to a loss of $13,059 million for the same period in 2024[75] - Adjusted EBITDA for the U.S. Healthcare segment was $158 million for the three months ended February 28, 2025, up from $17 million in the same period last year[75] Other Financial Metrics - The company incurred acquisition-related amortization expenses of $250 million for the three months ended February 28, 2025, compared to $270 million for the same period in 2024[74] - The effective tax rate (GAAP) for the three months ended February 28, 2025, was 5.0%, compared to 6.0% for the same period in 2024[79] - Adjusted effective tax rate excluding adjusted equity earnings in Cencora was 27.7% for the three months ended February 28, 2025, compared to (29.4)% for the same period in 2024[79] - The company recognized a pre-tax non-controlling interest benefit due to the amendment of the VillageMD Secured Loan, which is not indicative of normal operating performance[72] - The company made incremental pension contributions of $379 million during the three months ended February 29, 2024, as part of a bulk annuity policy acquisition[80]

Revenue Results - SES AI Corporation reported preliminary unaudited revenue results for Q1 2025, with estimates subject to finalization[4] - The financial information provided is preliminary and based on management's estimates as of the press release date[5] Financial Reporting Standards - The company emphasizes that preliminary estimates should not replace full financial statements prepared in accordance with GAAP[5]

Revenue Performance - Generated net revenue of $186 million in Q3, with $193 million in constant currency; impacted by strategic initiatives and SKU rationalization by $13 million [2] - Cannabis net revenue was $54.3 million, down from $63.4 million in the prior year quarter; gross margin increased to 41% [15] - Beverage alcohol net revenue increased to $55.9 million, with gross margin rising to 36% [15] - Distribution net revenue increased 8% to $61.5 million, with gross margin at 9% [15] - Wellness net revenue increased 5% to $14.1 million, with gross margin at 32% [15] - Total net revenue for the three months ended February 28, 2025, was $185,780,000, a decrease of 1% compared to $188,340,000 for the same period in 2024 [34] - The cannabis business generated $54,274,000 in revenue for the three months ended February 28, 2025, down 14% from $63,432,000 in the prior year [34] - The beverage business accounted for 30% of total net revenue for the three months ended February 28, 2025, generating $55,921,000 [34] - Total net revenue for Q3 2025 reached $192,949, a 2% increase from $188,340 in Q3 2024 [35] - Cannabis business revenue decreased to $54,274 in Q3 2025, down 14% from $63,432 in Q3 2024 [36] - Distribution business revenue increased to $65,054, up 15% from $56,794 in Q3 2024 [35] - Beverage business revenue for Q3 2025 was $55,921, a slight increase from $54,688 in Q3 2024 [38] Profitability and Loss - Gross profit increased by 5% to $52 million, with gross margin rising 200 bps to 28% compared to the prior year quarter [15] - Net loss of $(793.5) million due to approximately $700 million of non-cash impairment and other charges; adjusted net loss was $(2.9) million [15] - Operating loss for the three months ended February 28, 2025, was $(759,931,000), an increase of 826% compared to $(82,098,000) in the same period last year [32] - Net loss attributable to stockholders of Tilray for the three months ended February 28, 2025, was $(789,436,000), a 752% increase from $(92,701,000) in the prior year [32] - The company reported a comprehensive loss of $(798,923,000) for the three months ended February 28, 2025, which is a 628% increase compared to $(109,679,000) in the prior year [32] - The net loss for the three months ended February 28, 2025, was $(793,534,000), a significant increase of 656% compared to $(104,983,000) in the same period of 2024 [41] Financial Position - Reduced total debt by $71 million, with $248 million available in cash and marketable securities, resulting in net debt to trailing twelve months EBITDA of less than 1.0x [8] - Total current assets as of February 28, 2025, were $686.29 million, compared to $677.71 million as of May 31, 2024, reflecting a slight increase [29] - Cash and cash equivalents decreased to $199.96 million from $228.34 million over the same period [29] - Total liabilities decreased to $701.04 million from $778.49 million, indicating improved financial health [30] - The company’s accumulated deficit increased to $3.57 billion as of February 28, 2025, from $2.66 billion as of May 31, 2024 [30] - Cash and cash equivalents at the end of the period were $199,956,000, reflecting a 37% increase from $146,253,000 at the end of the previous year [33] - Working capital as of February 28, 2025, was $424,115, an increase from $302,111 in February 2024 [39] Operational Efficiency - Implementing AI and advanced horticulture automation technology to enhance operational efficiency and reduce costs [9] - Adjusted EBITDA is calculated by excluding various non-operating expenses, providing a clearer view of operational performance [22] - The company reported an adjusted net loss attributable to stockholders, which excludes non-operating income and other adjustments [23] Strategic Initiatives - Revised fiscal year 2025 guidance for net revenue to $850 million to $900 million, with potential adjustments for strategic initiatives totaling approximately $50 million [11] - The company is focusing on market expansion and new product development as part of its strategic initiatives [31] Cash Flow and Investments - Free cash flow is derived from net cash flow from operating activities minus capital investments, providing insight into liquidity [26] - Net cash used in operating activities for the nine months ended February 28, 2025, was $(81,792,000), a 33% increase from $(61,612,000) in the same period last year [33] - Total investments in capital and intangible assets rose by 40% year-over-year from $(25,753) thousand to $(18,373) thousand [44] - Year-over-year cash flow from operating activities showed a significant decline of 33% from $(81,792) thousand to $(61,612) thousand [44] - Free cash flow improved to $(19,973) thousand, a decrease of $4,115 thousand or 17% from $(24,088) thousand [44] - Adjusted free cash flow showed a substantial decline to $(18,165) thousand from $641 thousand, a change of $(18,806) thousand or 2934% [44]

Exhibit 99.1 RPM Reports Fiscal 2025 Third-Quarter Results MEDINA, OH – April 8, 2025 – RPM International Inc. (NYSE: RPM), a world leader in specialty coatings, sealants and building materials, today reported financial results for its fiscal 2025 third quarter ended February 28, 2025. Frank C. Sullivan, RPM chairman and CEO commented, "The unfavorable weather conditions we discussed in early January continued and became more widespread as the third quarter progressed. Unseasonably cold weather in the south ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 20-F (Mark One) ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(B) OR 12(G) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☐ SHELL COMPANY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF ...

Financial Performance - Net sales for the fiscal year ended December 28, 2024, were $265.0 million, a decrease of 4.1% compared to $276.3 million in 2023[106][108] - Gross profit decreased by 11.3% to $65.5 million, with gross profit as a percentage of net sales dropping from 26.7% in 2023 to 24.7% in 2024[106][109] - Operating loss for 2024 was $5.9 million, a significant decline from an operating income of $5.0 million in 2023, primarily due to increased costs and lower sales volume[106][113] - The net loss for 2024 was $13.0 million, or $0.88 per diluted share, compared to a net loss of $2.7 million, or $0.18 per diluted share, in 2023[106][118] Cash Flow and Debt - Cash provided by continuing operations was $3.6 million, with a reduction in inventories generating $9.4 million[120] - The company had $50.0 million of outstanding indebtedness under its senior credit facility as of December 28, 2024, maturing on October 30, 2025[123] - On February 25, 2025, the company entered into a new three-year $75.0 million senior secured credit facility with MidCap Financial IV Trust[123] - The unused borrowing availability under the revolving credit facility was $9.9 million as of December 28, 2024[129] - The company entered into a $10.0 million principal amount USDA Guaranteed term loan with a minimum interest rate of 5.00% and a term of 25 years[130] - The company also secured a $15.0 million principal amount USDA Guaranteed term loan with a minimum interest rate of 5.00% and a term of 10 years[131] Expenses and Income - Selling and administrative expenses decreased to $69.9 million in 2024 from $74.1 million in 2023, representing 26.4% of net sales[106][110] - Other operating income was a net expense of $200 thousand in 2024, compared to income of $9.2 million in 2023 due to the sale and leaseback of the Adairsville distribution center[106][111] Compliance and Valuation - The company received notice from Nasdaq regarding non-compliance with the minimum bid price requirement, leading to delisting from Nasdaq effective October 3, 2024[105][122] - Valuation allowances increased by $3.8 million related to net deferred tax assets and specific federal and state net operating losses for the year ended December 28, 2024[136] - At December 28, 2024, the company had valuation allowances of $24.7 million compared to $21.0 million at December 30, 2023[146] Interest Rates and Liabilities - As of December 28, 2024, the applicable margin on the revolving credit facility was 2.50% for SOFR and 1.50% for Prime due to the fixed charge coverage ratio being below 1.10 to 1.00[127] - The weighted-average interest rate on borrowings outstanding under the revolving credit facility was 7.18% at December 28, 2024, compared to 8.15% for December 30, 2023[128] - Approximately 86% of the company's total debt, amounting to $71,960, was subject to floating interest rates as of December 28, 2024[148] - A one-hundred basis point fluctuation in the variable interest rates applicable to floating rate debt would have an annual pre-tax impact of approximately $720[148] Environmental Liabilities - The company has a reserve of $2.2 million for environmental liabilities associated with discontinued operations as of December 28, 2024[138]

Company Information - The company is listed on the New York Stock Exchange under the trading symbol AC[3] - The company is incorporated in Delaware with IRS Employer Identification No. 47-3965991[3] - The address of the principal executive offices is 191 Mason Street, Greenwich, CT 06830[3] Financial Reporting - Associated Capital Group, Inc. announced a preliminary range for its book value per share for the quarter ended March 31, 2025[4] - The press release related to the financial results is filed as Exhibit 99.1[4] - The report was signed by Ian J. McAdams, Chief Financial Officer, on April 7, 2025[8] - The filing is made pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934[4] - The report does not include detailed financial statements or operational results[5] - The information provided is not deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934[5] - The company has not indicated if it is an emerging growth company[3]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 20-F (Mark One) ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ______ to ______ Commission File No.: 001-39481 PAINREFORM LTD. ( ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 Or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 001-39642 CXApp Inc. (Exact name of registrant as specified in its charter) | Delaware | 85-2104918 | | --- | --- | | (State or other jurisd ...